CY1111512T1 - Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων - Google Patents

Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων

Info

Publication number
CY1111512T1
CY1111512T1 CY20111100121T CY111100121T CY1111512T1 CY 1111512 T1 CY1111512 T1 CY 1111512T1 CY 20111100121 T CY20111100121 T CY 20111100121T CY 111100121 T CY111100121 T CY 111100121T CY 1111512 T1 CY1111512 T1 CY 1111512T1
Authority
CY
Cyprus
Prior art keywords
optional
treatment
life anxiety
opioid
anxiety
Prior art date
Application number
CY20111100121T
Other languages
English (en)
Inventor
Wolfgang Fleischer
Karen Reimer
Karin Gawora
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1111512T1 publication Critical patent/CY1111512T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Disintegrating Or Milling (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία πόσιμη μορφή δόσεως ελεγχόμενης απελευθερώσεως οπιοειδούς που περιλαμβάνει τουλάχιστον ένα οπιοειδές για την κατασκευή ενός φαρμακευτικού σκευάσματος για την αγωγή ασθενών με σύνδρομο ανήσυχου ποδός (RLS).
CY20111100121T 2004-06-08 2011-02-03 Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων CY1111512T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04013469A EP1604667A1 (en) 2004-06-08 2004-06-08 Opioids for the treatment of the restless leg syndrome
EP05754710A EP1781291B9 (en) 2004-06-08 2005-06-01 Opioids for the treatment of the restlessness of the lower limbs

Publications (1)

Publication Number Publication Date
CY1111512T1 true CY1111512T1 (el) 2015-08-05

Family

ID=34925286

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100121T CY1111512T1 (el) 2004-06-08 2011-02-03 Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων

Country Status (25)

Country Link
US (2) US20070185147A1 (el)
EP (3) EP1604667A1 (el)
JP (2) JP2008501742A (el)
KR (2) KR101200869B1 (el)
CN (2) CN1984659A (el)
AT (1) ATE486603T1 (el)
AU (1) AU2005251445C1 (el)
BR (1) BRPI0511300A (el)
CA (1) CA2569742C (el)
CY (1) CY1111512T1 (el)
DE (1) DE602005024571D1 (el)
DK (1) DK1781291T3 (el)
ES (1) ES2355247T3 (el)
HR (1) HRP20110049T2 (el)
IL (1) IL179896A (el)
ME (1) ME01238B (el)
MX (1) MXPA06014391A (el)
NO (1) NO337890B1 (el)
NZ (1) NZ552430A (el)
PL (1) PL1781291T3 (el)
PT (1) PT1781291E (el)
RS (1) RS51573B (el)
SI (1) SI1781291T1 (el)
WO (1) WO2005120506A1 (el)
ZA (1) ZA200610477B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234362C (zh) 1997-12-22 2006-01-04 欧罗赛铁克股份有限公司 阿片样激动剂/阿片样拮抗剂组合物
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
KR101479388B1 (ko) 2010-05-10 2015-01-05 유로-셀티큐 에스.에이. 활성제 로딩된 과립과 추가의 활성제와의 조합물
CH705273B1 (de) 2010-05-10 2016-06-15 Euro Celtique Sa Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
AU2011288413B2 (en) * 2010-08-13 2014-05-22 Mundipharma Pty Limited Use of binders for manufacturing storage stable formulations
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (el) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (el) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (el) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
CN1234362C (zh) * 1997-12-22 2006-01-04 欧罗赛铁克股份有限公司 阿片样激动剂/阿片样拮抗剂组合物
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
CZ297284B6 (cs) * 1998-03-27 2006-10-11 Pharmacia & Upjohn Company Farmaceutiký prostredek pro lécbu syndromu neklidných nohou
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
IL157932A0 (en) * 2001-04-19 2004-03-28 Warner Lambert Co Fused bicyclic or tricyclic amino acids
ATE493130T1 (de) * 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2778114A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
EP1416842B1 (en) * 2001-07-18 2008-12-31 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003026676A1 (en) * 2001-09-24 2003-04-03 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
LT2425821T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
AU2005251445C1 (en) 2009-04-09
EP1604667A1 (en) 2005-12-14
MXPA06014391A (es) 2007-02-19
JP2011137020A (ja) 2011-07-14
ES2355247T3 (es) 2011-03-24
ZA200610477B (en) 2007-12-27
BRPI0511300A (pt) 2007-12-04
SI1781291T1 (sl) 2011-02-28
DK1781291T3 (da) 2011-02-07
CA2569742C (en) 2011-03-22
RS51573B (en) 2011-08-31
EP1781291A1 (en) 2007-05-09
CA2569742A1 (en) 2005-12-22
NZ552430A (en) 2008-09-26
KR101200869B1 (ko) 2012-11-13
CN1984659A (zh) 2007-06-20
EP1781291B9 (en) 2011-08-31
NO337890B1 (no) 2016-07-04
AU2005251445B8 (en) 2008-09-18
JP5774865B2 (ja) 2015-09-09
ME01238B (me) 2011-08-31
EP2255808A2 (en) 2010-12-01
JP2008501742A (ja) 2008-01-24
EP1781291B1 (en) 2010-11-03
IL179896A (en) 2013-07-31
CN103394090A (zh) 2013-11-20
IL179896A0 (en) 2007-05-15
AU2005251445A1 (en) 2005-12-22
ES2355247T9 (es) 2011-11-03
EP2255808A3 (en) 2011-05-11
PL1781291T3 (pl) 2011-06-30
WO2005120506A1 (en) 2005-12-22
PT1781291E (pt) 2011-01-06
KR20070037485A (ko) 2007-04-04
KR20090089921A (ko) 2009-08-24
AU2005251445B2 (en) 2008-09-04
DE602005024571D1 (de) 2010-12-16
HRP20110049T1 (en) 2011-02-28
US20120172387A1 (en) 2012-07-05
HRP20110049T2 (hr) 2011-10-31
ATE486603T1 (de) 2010-11-15
US20070185147A1 (en) 2007-08-09
NO20070113L (no) 2007-03-02

Similar Documents

Publication Publication Date Title
CY1111512T1 (el) Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων
DK1765349T3 (da) Opioider til behandling af kronisk obstruktiv lungesygdom
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
ATE474564T1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
SMT201200014B (it) Nalmefene cloridrato diidrato.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
MX2011011618A (es) Agentes terapeuticos 713.
NO20072720L (no) Farmasoytiske sammensetninger basert pa NK2-antagonister for pediatrisk bruk
DE602007008567D1 (de) Pharmazeutische Zusammensetzungen zur oralen Verabreichung bei der Behandlung von Adipositas-Patienten
ITMI20060712A1 (it) Uso di aminaftone per la preparazione di un medicamento per il trattamento delle arteriopatie
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
EA200970968A1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидо-4-пиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
ES1056960Y (es) Aparato dental intra-oral para el tratamiento del ronquido y la apnea del sueño.
MX2008011017A (es) Compuestos de receptor sigma.
TW200738640A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
MY166018A (en) Composition and method for prevention and treatment of alzheimer's disease
CR8212A (es) Omega-carboxiaril-difenil-urea sustituida con fluor para el tratamiento y la prevencion de enfermedades y afecciones